Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc reports news on a hub-and-spoke biotherapeutics model built around internal programs and Founded Entities. Recurring updates cover portfolio strategy, annual and half-year results, capital allocation, and clinical development across medicines for inflammatory, immunological, oncologic, gastrointestinal, neurological and neuropsychiatric disorders.
Company news frequently includes deupirfenidone for idiopathic pulmonary fibrosis, LYT-200, a fully human anti-galectin-9 monoclonal antibody for myeloid malignancies, and Seaport Therapeutics programs using the Glyph platform for oral neuropsychiatric medicines. Other developments include scientific publications, clinical data releases, board and leadership changes, shareholder voting matters and capital-structure disclosures tied to PureTech and its Founded Entities.
PureTech (Nasdaq: PRTC) announced that the FDA and European Commission granted Orphan Drug Designation to deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). Phase 2b ELEVATE IPF showed a 91 mL FVC advantage versus placebo at 26 weeks (p=0.02) and a -32.8 mL FVC decline at 52 weeks. Celea Therapeutics plans Phase 3 SURPASS-IPF in H1 2026 and intends to finalize financing in H1 2026 to support initiation.
PureTech (Nasdaq: PRTC) announced that Chief Executive Officer Robert Lyne will present at the 44th annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 4:30 PM PST / 7:30 PM EST.
A live webcast of the presentation will be available via the company investor site at https://investors.puretechhealth.com. The announcement identifies the presentation date, time, presenter, and webcast access for investors and stakeholders.
PureTech (Nasdaq: PRTC) appointed Robert Lyne as Chief Executive Officer and board member, effective December 18, 2025. Mr. Lyne has served as Interim CEO since July 2025 and joined PureTech in January 2024 as Chief Portfolio Officer.
He said the company’s immediate priority is to secure financing for new Founded Entity Celea Therapeutics after a successful End-of-Phase 2 FDA meeting, targeting a close in first half of 2026, after which PureTech expects its operational run rate to reduce significantly. PureTech is also pursuing 2026 financing for Gallop Oncology. Management plans a streamlined operating structure, reduced overhead, and disciplined, capital-efficient investment with potential future capital returns once Celea is fully financed.
PureTech (Nasdaq: PRTC) announced that Celea Therapeutics completed an End-of-Phase 2 meeting with the FDA for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF).
The FDA feedback supports advancing to a global pivotal Phase 3 SURPASS-IPF trial, planned to start in the first half of 2026, and indicates a streamlined 505(b)(2) pathway could be possible if a single Phase 3 is successful and supported by the totality of deupirfenidone data. Phase 3 will be a 52-week, randomized, double-blind head-to-head trial versus pirfenidone, with primary endpoint change in absolute FVC at week 52.
Phase 2b ELEVATE-IPF results cited: deupirfenidone 825 mg TID showed a 91 mL FVC advantage vs placebo at 26 weeks and a maintained -32.8 mL FVC decline over 52 weeks in extension. Celea expects to finalize financing in early 2026 to support Phase 3 initiation.
Gallop Oncology (Nasdaq:PRTC) announced initial topline Phase 1b results for LYT-200 in relapsed/refractory AML and high-risk MDS, showing a favorable safety profile and encouraging efficacy.
At the proposed Phase 2 dose (12 mg/kg) in combination with venetoclax/hypomethylating agent: 38% combined complete response, 97% disease control, and initial median overall survival of 13.2 months. Monotherapy median overall survival was 6.5 months. No LYT-200–related serious adverse events or dose‑limiting toxicities observed (n=101). Final overall survival data expected in 1H 2026; additional details to be presented at ASH 2025 on December 6, 2025.
PureTech (Nasdaq: PRTC) announced that Founded Entity Gallop Oncology will present updated Phase 1b data for LYT-200, an anti‑galectin‑9 antibody, at ASH on December 6, 2025. The ASH abstract reflects data as of July 8, 2025 with additional analyses expected at the meeting.
Data cover 31 monotherapy and 39 combination (LYT-200 + venetoclax/hypomethylating agents) participants dosed ≥7.5 mg/kg. Combination results include 12 CRs, 1 PR, 1 MLFS (CR rate >30% as of cut‑off). No dose‑limiting toxicities or LYT‑200‑related serious adverse events, discontinuations, or deaths were reported. Topline efficacy data expected Q4 2025; topline survival data expected H1 2026.
PureTech (Nasdaq: PRTC) announced new Phase 2b ELEVATE IPF sub-analyses presented at CHEST 2025 on October 22, 2025 showing deupirfenidone maintained a consistent safety and efficacy profile in patients aged ≥75 years versus 75 years.The analysis compared deupirfenidone 825 mg TID and 550 mg TID to placebo and pirfenidone 801 mg TID, reporting similar treatment-emergent adverse events across age groups (subgroups: n=91 for ≥75; n=166 for <75) and comparable nausea rates across doses.
PureTech (NASDAQ:PRTC) announced promising new data from its Phase 2b open-label extension study of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). The study demonstrated that patients switching from placebo or pirfenidone to deupirfenidone achieved lung function stabilization with favorable tolerability.
Key findings include patients switching from placebo to deupirfenidone showing a mean FVC change of +20.0 mL, while those switching from pirfenidone showed -23.1 mL. The drug maintained its efficacy over 52 weeks, with an overall FVC decline of -32.8 mL, comparable to natural decline in healthy older adults. The treatment was well-tolerated, with common side effects including nausea, dyspepsia, upper respiratory infections, and cough.
PureTech is currently engaging with regulators and expects to provide an update on Phase 3 trial design in Q4 2025.
PureTech's (NASDAQ: PRTC) Founded Entity, Seaport Therapeutics, has initiated a Phase 1 clinical trial of GlyphAgo™ (SPT-320), marking its second therapeutic candidate to enter clinical development. GlyphAgo is an oral prodrug of agomelatine designed to treat Generalized Anxiety Disorder (GAD).
The novel drug aims to overcome agomelatine's key limitation of first-pass liver metabolism by utilizing Seaport's proprietary Glyph™ platform to shift absorption toward intestinal lymphatics. Preclinical studies showed over 50% lymphatic transport and 10-fold increased plasma exposure compared to agomelatine alone.
The Phase 1 study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers, with the goal of achieving therapeutic levels at lower doses while reducing liver exposure.
PureTech Health (NASDAQ/LSE: PRTC) released its H1 2025 results, highlighting strong financial position with $319.6M in PureTech-level cash and operational runway into 2028. The company announced strategic refinements to its hub-and-spoke biotherapeutics model, focusing on capital-efficient development of high-potential programs.
Key developments include the launch of Celea Therapeutics to advance deupirfenidone, with Phase 3 trial initiation planned for H1 2026, and continued progress in Gallop Oncology's Phase 1b trial. The company maintains significant interests in various Founded Entities and retains rights to milestone payments and royalties from Karuna's Cobenfy™ following its acquisition by Bristol Myers Squibb.
Under new interim leadership with Sharon Barber-Lui as Board Chair and Robert Lyne as CEO, PureTech is strengthening its UK market presence and plans to add two new directors with UK capital markets expertise.